A multicenter Phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary results

被引：0
|
作者：
De Tursi, M.
Carella, C.
Ricevuto, E.
Marchetti, P.
Gennari, A.
Orlandini, C.
Frassoldati, A.
Conte, P.
Iacobelli, S.
机构：
[1] Univ G dAnnunzio, Dept Oncol & Neurosci, Chieti, Italy
[2] Univ Aquila, Dept Oncol, I-67100 Laquila, Italy
[3] Univ Pisa, Dept Oncol, I-56100 Pisa, Italy
[4] Univ Modena, Dept Oncol, I-41100 Modena, Italy
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：116 / 116
页数：1
相关论文
共 50 条
  • [31] MULTICENTER PHASE-II STUDY OF LOW-DOSE INTRAVESICAL EPIRUBICIN IN THE TREATMENT OF SUPERFICIAL BLADDER-CANCER
    WHELAN, P
    CUMMING, JA
    GARVIE, WHH
    HARGREAVE, TB
    KIRK, D
    NEWLING, DWW
    ROBINSON, MRG
    SMITH, PH
    BRITISH JOURNAL OF UROLOGY, 1991, 67 (06): : 600 - 602
  • [32] A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Hope S. Rugo
    A. Jo Chien
    Sandra X. Franco
    Alison T. Stopeck
    Alexa Glencer
    Soumi Lahiri
    Michael C. Arbushites
    Janet Scott
    John W. Park
    Clifford Hudis
    Ben Nulsen
    Maura N. Dickler
    Breast Cancer Research and Treatment, 2012, 134 : 13 - 20
  • [33] Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC). First stage results
    Brufsky, A
    Orlando, M
    Fox, K
    Jame, A
    Katherine, T
    Franco, S
    Vincent, H
    Terry, E
    LaTrice, H
    Steven, S
    Allen, M
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S128 - S128
  • [34] Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer:: Results of a multicenter phase II study
    Palmeri, S
    Vaglica, M
    Spada, S
    Filippelli, G
    Farris, A
    Palmeri, L
    Massidda, B
    Misino, A
    Ferraù, F
    Comella, G
    Leonardi, V
    Condemi, G
    Mangiameli, A
    De Cataldis, G
    Macaluso, MC
    Cajozzoo, M
    Iannitto, E
    Danova, M
    ONCOLOGY, 2005, 68 (4-6) : 438 - 445
  • [35] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Goldfarb, Shari Beth
    Theodoulou, Maria
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Fasano, Julie
    Comen, Elizabeth Anne
    Gajria, Devika
    Moynahan, Mary Ellen
    Traina, Tiffany A.
    Chen, Melanie
    Hamilton, Nicola
    Patil, Sujata
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Theodoulou, Maria
    Goldfarb, Shari Beth
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Sklarin, Nancy T.
    Comen, Elizabeth Anne
    Fasano, Julie
    Gajria, Devika
    Drullinsky, Pamela
    Murphy, Conleth G.
    Syldor, Angemael
    Patil, Sujata
    Liu, Jennifer
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [37] Phase II study with paclitaxel (P) and novantrone (N) as first line treatment in metastatic breast cancer (MBC).
    Fontaine, C
    Neyns, B
    Van Erps, J
    Dewaele, A
    De Grève, J
    ANNALS OF ONCOLOGY, 2000, 11 : 37 - 38
  • [38] A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
    Tryfonidis, K.
    Boukovinas, I.
    Xenidis, N.
    Christophyllakis, C.
    Papakotoulas, P.
    Politaki, E.
    Malamos, N.
    Polyzos, A.
    Kakolyris, S.
    Georgoulias, V.
    Mavroudis, D.
    BREAST, 2013, 22 (06) : 1171 - 1177
  • [39] Docetaxel versus epirubicin/cyclophosphamide(EC) as first-line therapy in metastatic breast cancer (MBC): results from the randomized phase II TIPP study
    不详
    BREAST, 2005, 14 : S41 - S41
  • [40] Phase II Study of Vinorelbine Plus Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines and Taxanes
    Kwon, H.
    Oh, S. Y.
    Kim, S. H.
    Lee, S.
    Lee, J. H.
    Kim, H. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S353 - S353
12345